Page 11234..10..»

Archive for the ‘Global News Feed’ Category

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Saturday, January 1st, 2022

NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that the Company achieved alignment with the FDA Division of Neurology 1 (“FDA”) to move forward in myasthenia gravis (“MG”). Immunovant plans to start its Phase 3 study for batoclimab in MG in the first half of calendar year 2022.

Original post:
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Read More...

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Saturday, January 1st, 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (“Kreos”) and Pontifax Medison Debt Financing (“Pontifax”).

Continue reading here:
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

Read More...

Gritstone Announces Presentations during Three Upcoming Investor Conferences

Saturday, January 1st, 2022

EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in the following upcoming investor conferences in January.

Read this article:
Gritstone Announces Presentations during Three Upcoming Investor Conferences

Read More...

Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s…

Saturday, January 1st, 2022

Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations Meet with InMed’s CEO Eric A. Adams, Shane Johnson, SVP and General Manager of BayMedica and Chris Meiering, VP of Commercial Operations

Originally posted here:
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s...

Read More...

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

Saturday, January 1st, 2022

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

Read the original post:
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

Read More...

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Saturday, January 1st, 2022

- Positive Phase 3 data in 2nd/3rd line NSCLC (Dublin-3): Superior efficacy benefit in plinabulin and docetaxel combination in overall survival, 2-year and 3-year OS rate, PFS, ORR, and significant reduction of grade 4 neutropenia vs. docetaxel alone

Read the original post:
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Read More...

Lotus Ventures Inc. Reports Fiscal 2021 Results

Saturday, January 1st, 2022

VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lotus Ventures Inc. (CSE: J) (OTC: LTTSF) (“Lotus” or the “Company”), a trusted cannabis producer in Canada is pleased to report its Fiscal 2021 full year results and a second consecutive year reporting a profit for the year ended August 31, 2021.

View post:
Lotus Ventures Inc. Reports Fiscal 2021 Results

Read More...

Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Saturday, January 1st, 2022

Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022 Company now expects to release topline 52-week results from MAESTRO-NAFLD-1 in January 2022

View post:
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Read More...

Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

Saturday, January 1st, 2022

WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG was diluted below 50%. Biofrontera AG’s shareholding in Biofrontera Inc. of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG. Biofrontera Inc.’s common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BFRI” and “BFRIW,” respectively.

Continue reading here:
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

Read More...

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2…

Saturday, January 1st, 2022

MALVERN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021.

See the article here:
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2...

Read More...

Total number of shares and voting rights in Zealand Pharma at December 30, 2021

Saturday, January 1st, 2022

Company announcement – No. 78 / 2021

Read more:
Total number of shares and voting rights in Zealand Pharma at December 30, 2021

Read More...

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

Saturday, January 1st, 2022

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with institutional investors and accredited investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, to receive gross proceeds of approximately $6.0 million.

Here is the original post:
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

Read More...

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

Saturday, January 1st, 2022

THE WOODLANDS, Texas, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

Read the original here:
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

Read More...

Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease

Saturday, January 1st, 2022

Key Points:

Continue reading here:
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease

Read More...

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

Saturday, January 1st, 2022

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, the KOLs will lend their expertise and support to guide the education and clinical advancement efforts of the Human Acellular VesselTM (HAV) and help identify opportunities to advance the Company's early stage complex tissue constructs pipeline and platform.

View post:
Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

Read More...

MedMira Reports First Quarter Results FY2022

Saturday, January 1st, 2022

HALIFAX, Nova Scotia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2021.

More here:
MedMira Reports First Quarter Results FY2022

Read More...

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

Saturday, January 1st, 2022

–  Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein –

Go here to read the rest:
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

Read More...

Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

Saturday, January 1st, 2022

The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations The Phase 1 Study Will be Comprised of Two Parts: Phase 1a Dose-escalation that will Evaluate the Safety and Tolerability of NXP800 in Patients with Advanced Solid Tumors, Followed by a Phase 1b to Evaluate Preliminary Efficacy in Specific Populations

Continue reading here:
Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800

Read More...

Lui Franciosi Tracking Published Fall Numbers of Seniors During this COVID-19 Pandemic

Saturday, January 1st, 2022

VANCOUVER, British Columbia, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. is currently tracking the number of falls involving seniors and that have been reported in the public domain during this COVID-19 pandemic. In particular, government sites such as the Canadian Institute for Health Information, online media reports and survey portals from various countries are being searched to determine these numbers as well as the nature and location of the falls in designated senior housing such as long term care, assisted living and independent living. Lui Franciosi states, “During this pandemic, seniors have likely not had the same level of exercise and therefore their body core strength is not as optimal to prevent injury. It is known that falls are the leading cause of injuries among seniors, accounting for 61 per cent of injury-related deaths and 81 per cent of injury-related hospitalizations in Canada. There are close to 5,000 deaths each year linked to seniors’ falls and nearly 100,000 hospitalizations.” The aim of this work is to better understand how many of these falls are actually predictable and whether an algorithm could be developed to help healthcare staff and families prevent falls, especially in frequent fallers.

Read the rest here:
Lui Franciosi Tracking Published Fall Numbers of Seniors During this COVID-19 Pandemic

Read More...

Cronos Group Provides Bi-Weekly MCTO Status Update

Saturday, January 1st, 2022

TORONTO, Dec. 31, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”).

Go here to read the rest:
Cronos Group Provides Bi-Weekly MCTO Status Update

Read More...

Page 11234..10..»


2022 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick